GL1X · GenesisL1 explorer

Research workbench

Co-crystal structure of human PRMT9 in complex with MT221 inhibitor

Analyse Co-crystal structure of human PRMT9 in complex with MT221 inhibitor in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
7T39
Type
protein
Length
613 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Protein arginine N-methyltransferase 9
EC
2.1.1.320
UniProt
Q6P2P2
Ligands
EJB
Pockets
6 · best druggability 0.73

Structure

x-ray diffraction · 1 distinct chain · 24% helix, 34% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AProtein arginine N-methyltransferase 9 (EC 2.1.1.320)protein61324% helix, 34% strandQ6P2P2

Ligands and binding sites

  • EJB · 7-[5-S-(4-{[(2-ethylpyridin-3-yl)methyl]amino}butyl)-5-thio-beta-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

6 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13690.730.8445EJB
24600.690.8048empty
31100.610.8723empty
4850.420.7916empty
51290.410.7520empty

Compared structures

  • 7T39 · Co-crystal structure of human PRMT9 in complex with MT221 inhibitor · the same entry in another collection · chain A against A, TM-score 1.00
  • Q6P2P2 · AlphaFold monomer V2.0 prediction for protein arginine N-methyltransferase 9 (Q6P2P2) · a predicted model of the same protein · chain A against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.